Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics Inc. (APGE) news coverage focuses on clinical trial developments, pipeline advancements, and regulatory milestones for the company's antibody-based therapies targeting dermatological and respiratory diseases. As a clinical-stage biotechnology company, Apogee's newsflow centers on trial enrollment updates, interim data releases, and investigational new drug applications that signal progress in its therapeutic development programs.
Investors tracking Apogee Therapeutics news can expect updates on patient dosing announcements, clinical trial results across multiple pipeline candidates, and presentations at medical conferences where the company discloses efficacy and safety data. Biotechnology companies at Apogee's development stage generate news through FDA interactions, clinical protocol modifications, and partnership announcements that may accelerate or fund pipeline programs.
This news feed provides comprehensive coverage of material events affecting Apogee's clinical programs, including trial initiations, data readouts, regulatory submissions, and capital raising activities that fund ongoing research. For biotechnology investors, these developments offer insight into the company's progress toward potential drug approvals and commercialization milestones. Bookmark this page to track clinical developments and regulatory events that may impact Apogee Therapeutics's therapeutic pipeline and business trajectory.
Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1b results for zumilokibart (APG777) in 19 adults with mild-to-moderate asthma, showing a maximum mean FeNO reduction of 45 ppb (60% from baseline) after one 720 mg dose and durable FeNO suppression through 16 weeks (and through 32 weeks for patients with follow-up).
Zumilokibart was well tolerated with no Grade 3+ TEAEs, no conjunctivitis, injection-site reactions, or ADAs. Company highlights expected 2026 milestones: APEX Part A 52-week data in Q1 2026, Part B 16-week induction data in Q2 2026 (Part B enrolled 347 patients), potential Phase 3 start in 2H 2026, and a potential commercial launch in 2029. Cash of $913 million provides runway into 2H 2028.
Apogee Therapeutics (Nasdaq: APGE) will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026.
The company will host a conference call and live webcast on January 6, 2026 at 8:00 a.m. ET to discuss the interim data. The live webcast can be accessed via the company’s investor website at https://investors.apogeetherapeutics.com/news-events/events and a replay will be available after the call.
Apogee Therapeutics (NASDAQ: APGE) reported Q3 2025 results and pipeline progress on Nov 10, 2025. The company expects four clinical readouts in 2026 including APG777 Phase 1b in asthma (Q1 2026), APEX 52-week Part A maintenance data in AD (Q1 2026), APEX 16-week Part B in AD (Q2 2026), and an APG279 head-to-head interim readout vs DUPIXENT in 2H 2026.
Interim Phase 1 data for APG333 showed a ~55-day half-life, biomarker suppression to six months and support for quarterly or less frequent dosing in combination APG273. The company completed a $345M offering, with pro forma cash of $913M as of Sept 30, 2025, supporting runway into 2H 2028. Q3 operating metrics: R&D $54.2M, G&A $17.1M, net loss $65.0M.
Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1 results for APG333, a half-life–extended TSLP antibody, from a first‑in‑human, single‑ascending dose study in 32 healthy volunteers on Nov 10, 2025. Key findings: an optimized PK profile with an approximate 55‑day half‑life, durable suppression of eosinophils and IL‑5 out to 6 months after one dose, and tolerability up to 1,000 mg. Results support potential 3‑ to 6‑month dosing and development of a quarterly co‑formulation with APG777 (APG273).
Apogee Therapeutics (Nasdaq: APGE) announced management will participate in five investor conferences in November–December 2025 with scheduled fireside chats and webcasts.
Conferences and times: Guggenheim Healthcare – Nov 11, 2025 at 1:30 p.m. ET; Stifel Healthcare – Nov 12, 2025 at 11:20 a.m. ET; TD Cowen Immunology & Inflammation Virtual Summit – Nov 13, 2025 at 12:30 p.m. ET; Jefferies London Healthcare – Nov 19, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET; Citi Global Healthcare – Dec 3, 2025 at 9:45 a.m. ET.
A live and archived webcast of the fireside chats will be available on the company’s Investors & News & Events webpage.
Apogee Therapeutics (Nasdaq: APGE) closed an underwritten public offering on Oct. 10, 2025, raising approximately $345 million in gross proceeds.
The offering comprised 8,048,782 shares of common stock (including full exercise of the underwriters’ 1,097,561‑share option) and pre‑funded warrants to purchase up to 365,853 shares at a public offering price of $41.00 per share (pre‑funded warrants priced at $40.99999), with the pre‑funded warrants exercisable immediately at an exercise price of $0.00001 per share. Joint book‑running managers included Jefferies, BofA Securities, Guggenheim Securities and TD Cowen.
Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering to raise approximately $300 million in gross proceeds.
The offering includes 6,951,221 shares of common stock at $41.00 per share and pre-funded warrants to purchase up to 365,853 shares at $40.99999 each (exercise price $0.00001), exercisable immediately. The offering is expected to close on October 10, 2025, subject to customary conditions.
Underwriters have a 30-day option to purchase up to 1,097,561 additional shares. Joint book-runners include Jefferies, BofA Securities, Guggenheim Securities and TD Cowen. An automatically effective shelf registration was filed with the SEC on August 12, 2024.
Apogee Therapeutics (Nasdaq: APGE) announced on October 8, 2025 that it has commenced a proposed underwritten public offering of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company said it will grant underwriters a 30-day option to buy up to an additional 15% overallotment of the shares at the public offering price, subject to market conditions and underwriting terms.
Apogee intends to use net proceeds together with existing cash and marketable securities to fund preclinical studies, clinical trials, manufacturing, commercial readiness for its antibody programs, additional R&D, capital expenditures, working capital and general corporate purposes. The offering will be made by written prospectus and is subject to completion and SEC registration requirements.
Apogee Therapeutics (NASDAQ:APGE) announced that data from its Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025 in Paris. The presentation will highlight the drug's 16-week topline data, which successfully met primary and secondary endpoints.
APG777 stands out as the only biologic being tested for 3- and 6-month dosing intervals in maintenance treatment. The company will also present data on APG990 and their combination strategy with APG279, a coformulation designed to inhibit Type 1, Type 2, and Type 3 inflammation, potentially expanding their patient reach.
The presentations include a late-breaker oral session by Dr. Emma Guttman-Yassky and three poster presentations covering the APEX program, APG990's safety profile, and the combination therapy approach.
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Investors and interested parties can access both the live and archived versions of the fireside chat through the News & Events page in the Investors section of Apogee Therapeutics' website.
FAQ
What is the current stock price of Apogee Therapeutics (APGE)?
What is the market cap of Apogee Therapeutics (APGE)?
